visceral leishmaniasis
| 4 min read
A GLP-grade non-replicative Leishmania major parasite protects hamsters from lethal leishmaniasis infection, setting the stage for human clinical trials and the first potential vaccine for leishmaniasis.
Page 1 of 1 - 1 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Discovering deeper insights into malaria research
Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Accelerating RNA therapeutic testing with liver microphysiological platforms
Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Shining light on the subcellular proteome
Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
